By Fineline Cube 
US major Johnson & Johnson MedTech announced the launch of its VARIPULSE Platform in the Asia-Pacific region. This cutting-edge system is designed for catheter ablation procedures in atrial fibrillation (AFib), offering a significant advancement in the treatment of this common heart condition.
Innovative PFA Technology with Integrated Workflow
The VARIPULSE Platform is the first Pulsed Field Ablation (PFA) technology that combines ablation and mapping through an integrated workflow via the CARTO 3 System. This 3D electroanatomic mapping enables real-time visualization, enhancing precision, efficiency, and procedural accuracy for physicians treating AFib.
Enhanced Safety and Patient-Centered Treatment
The platform supports safe, efficient, and patient-centered treatment by requiring minimal to no fluoroscopy (X-ray). It also allows procedures to be conducted under deep or conscious sedation, providing greater flexibility and comfort for patients.
Clinical Validation of Efficacy and Safety
The efficacy and safety of the VARIPULSE Platform have been demonstrated in the inspIRE and admIRE clinical trials. These trials showed strong treatment effectiveness, reduced AFib recurrence rates, and favorable safety and tolerability profiles.-Fineline Info & Tech